For investors, the move signals a pathway to diversify BrainsWay's portfolio and expand its TAM. At-home neuromodulation offers potential for higher patient adoption and longer-term treatment engagement, while also creating opportunities for synergies between BrainsWay's established commercial infrastructure and Neurolief's innovation. This combination can strengthen BrainsWay's competitive edge in the growing market for depression treatment.